Literature DB >> 22730417

Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis.

Jeffrey R Curtis1, Angel Lanas, Ani John, David A Johnson, Kathy L Schulman.   

Abstract

OBJECTIVE: To estimate the incidence and risk factors for gastrointestinal (GI) perforation among patients with rheumatoid arthritis (RA).
METHODS: Claims from employer health insurance plans were used to identify RA patients and those hospitalized for upper or lower GI perforation. GI perforation cases were identified using both a sensitive and a specific definition. A Cox model using fixed and time-varying covariates was used to evaluate the risk of GI perforation.
RESULTS: Among 143,433 RA patients, and using a maximally sensitive GI perforation definition, 696 hospitalizations with perforation were identified. The rate of perforation was 1.70 per 1,000 person years (PYs; 95% confidence interval [95% CI] 1.58-1.83), and most perforations (83%) occurred in the lower GI tract. The rate of perforation was lower when a more specific GI perforation definition was used (0.87; 95% CI 0.78-0.96 per 1,000 PYs). Age and diverticulitis were among the strongest risk factors for perforation (diverticulitis hazard ratio [HR] 14.5 [95% CI 11.8-17.7] for the more sensitive definition, HR 3.9 [95% CI 2.5-5.9] for the more specific definition). Among various RA medication groups and compared to methotrexate, the risk of GI perforation was highest among patients with exposure to nonsteroidal antiinflammatory drugs (NSAIDs), concomitant nonbiologic disease-modifying antirheumatic drugs, and glucocorticoids. Biologic agents without glucocorticoid exposure were not a risk factor for perforation.
CONCLUSION: GI perforation is a rare but serious condition that affects patients with RA, most frequently in the lower GI tract. Clinicians should be aware of risk factors for GI perforation when managing RA patients, including age, history of diverticulitis, and use of glucocorticoids or NSAIDs.
Copyright © 2012 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22730417      PMCID: PMC3508293          DOI: 10.1002/acr.21764

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  20 in total

1.  Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding.

Authors:  Elvira L Massó González; Paola Patrignani; Stefania Tacconelli; Luis A García Rodríguez
Journal:  Arthritis Rheum       Date:  2010-06

2.  The changing face of hospitalisation due to gastrointestinal bleeding and perforation.

Authors:  A Lanas; L A García-Rodríguez; M Polo-Tomás; M Ponce; E Quintero; M A Perez-Aisa; J P Gisbert; L Bujanda; M Castro; M Muñoz; M D Del-Pino; S Garcia; X Calvet
Journal:  Aliment Pharmacol Ther       Date:  2011-01-05       Impact factor: 8.171

3.  The incidence of gastrointestinal perforations among rheumatoid arthritis patients.

Authors:  Jeffrey R Curtis; Fenglong Xie; Lang Chen; Claire Spettell; Raechele M McMahan; Joaquim Fernandes; Elizabeth Delzell
Journal:  Arthritis Rheum       Date:  2011-02

4.  Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding.

Authors:  Lisa L Strate; Yan L Liu; Edward S Huang; Edward L Giovannucci; Andrew T Chan
Journal:  Gastroenterology       Date:  2011-02-12       Impact factor: 22.682

5.  Concurrent drug use and the risk of perforated colonic diverticular disease: a population-based case-control study.

Authors:  David J Humes; Kate M Fleming; Robin C Spiller; Joe West
Journal:  Gut       Date:  2010-10-12       Impact factor: 23.059

6.  Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.

Authors:  Francis K L Chan; Angel Lanas; James Scheiman; Manuela F Berger; Ha Nguyen; Jay L Goldstein
Journal:  Lancet       Date:  2010-06-16       Impact factor: 79.321

7.  Data-driven identification of co-morbidities associated with rheumatoid arthritis in a large US health plan claims database.

Authors:  Hans Petri; Debra Maldonato; Noah Jamie Robinson
Journal:  BMC Musculoskelet Disord       Date:  2010-10-25       Impact factor: 2.362

8.  A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract.

Authors:  Francis K L Chan; Byron Cryer; Jay L Goldstein; Angel Lanas; David A Peura; James M Scheiman; Lee S Simon; Gurkirpal Singh; Martin J Stillman; Charles M Wilcox; Manuela F Berger; Aurora Breazna; William Dodge
Journal:  J Rheumatol       Date:  2009-11-02       Impact factor: 4.666

9.  Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population.

Authors:  Tracy Li; Ginger Smith Carls; Pantelis Panopalis; Sara Wang; Teresa B Gibson; Ron Z Goetzel
Journal:  Arthritis Rheum       Date:  2009-06-15

Review 10.  Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use.

Authors:  Sebastian Straube; Martin R Tramèr; R Andrew Moore; Sheena Derry; Henry J McQuay
Journal:  BMC Gastroenterol       Date:  2009-06-05       Impact factor: 3.067

View more
  17 in total

1.  Risk of gastrointestinal events among patients with sarcoidosis: a population-based study 1976-2013.

Authors:  Patompong Ungprasert; Cynthia S Crowson; Eric L Matteson
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

Review 2.  Tofacitinib: A Review in Rheumatoid Arthritis.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2017-12       Impact factor: 9.546

Review 3.  Gastrointestinal Perforations with Biologics in Patients with Rheumatoid Arthritis: Implications for Clinicians.

Authors:  Aprajita Jagpal; Jeffrey R Curtis
Journal:  Drug Saf       Date:  2018-06       Impact factor: 5.606

4.  A Case of Diverticular Perforation in a Young Patient with Rheumatoid Arthritis on Methotrexate.

Authors:  Ian Chang; Carla Guggenheim; Heather Laird-Fick
Journal:  Case Rep Med       Date:  2015-04-29

5.  Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab from Clinical Trial, Postmarketing, and Real-World Data Sources.

Authors:  Sharareh Monemi; Erhan Berber; Khaled Sarsour; Jianmei Wang; Kathy Lampl; Kamal Bharucha; Attila Pethoe-Schramm
Journal:  Rheumatol Ther       Date:  2016-07-15

Review 6.  What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?

Authors:  Jenny Humphreys; Kimme Hyrich; Deborah Symmons
Journal:  Arthritis Res Ther       Date:  2016-12-01       Impact factor: 5.156

7.  Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure.

Authors:  Gerd R Burmester; Peter Nash; Bruce E Sands; Kim Papp; Lori Stockert; Thomas V Jones; Huaming Tan; Ann Madsen; Hernan Valdez; Stanley B Cohen
Journal:  RMD Open       Date:  2021-05

8.  Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis.

Authors:  Marinella Patanè; Miriam Ciriaco; Serafina Chimirri; Francesco Ursini; Saverio Naty; Rosa Daniela Grembiale; Luca Gallelli; Giovambattista De Sarro; Emilio Russo
Journal:  Adv Pharmacol Sci       Date:  2013-05-12

9.  Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.

Authors:  Josef S Smolen; Monika M Schoels; Norihiro Nishimoto; Ferdinand C Breedveld; Gerd R Burmester; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Cem Gabay; Allan Gibofsky; Juan Jesus Gomez-Reino; Graeme Jones; Tore K Kvien; Miho Murakami; Neil Betteridge; Clifton O Bingham; Vivian Bykerk; Ernest H Choy; Bernard Combe; Maurizio Cutolo; Winfried Graninger; Angel Lanas; Emilio Martin-Mola; Carlomaurizio Montecucco; Mikkel Ostergaard; Karel Pavelka; Andrea Rubbert-Roth; Naveed Sattar; Marieke Scholte-Voshaar; Yoshiya Tanaka; Michael Trauner; Gabriele Valentini; Kevin L Winthrop; Maarten de Wit; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2012-11-21       Impact factor: 19.103

10.  Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.

Authors:  Stanley B Cohen; Yoshiya Tanaka; Xavier Mariette; Jeffrey R Curtis; Eun Bong Lee; Peter Nash; Kevin L Winthrop; Christina Charles-Schoeman; Krishan Thirunavukkarasu; Ryan DeMasi; Jamie Geier; Kenneth Kwok; Lisy Wang; Richard Riese; Jürgen Wollenhaupt
Journal:  Ann Rheum Dis       Date:  2017-01-31       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.